Matches in Wikidata for { <http://www.wikidata.org/entity/Q92392250> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q92392250 description "clinical trial" @default.
- Q92392250 description "ensayo clínico" @default.
- Q92392250 description "ensayu clínicu" @default.
- Q92392250 description "klinisch onderzoek" @default.
- Q92392250 description "клінічне випробування" @default.
- Q92392250 description "临床试验" @default.
- Q92392250 name "Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection" @default.
- Q92392250 name "Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection" @default.
- Q92392250 type Item @default.
- Q92392250 label "Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection" @default.
- Q92392250 label "Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection" @default.
- Q92392250 prefLabel "Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection" @default.
- Q92392250 prefLabel "Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection" @default.
- Q92392250 P1050 Q92392250-2EEE6EFE-F6D5-45E0-9B57-AF0719A16B29 @default.
- Q92392250 P1132 Q92392250-D6215124-47BE-4044-A070-F18B2A6C7742 @default.
- Q92392250 P1476 Q92392250-86F12EDD-2365-4ACA-8DDD-2ABE56E97AB0 @default.
- Q92392250 P17 Q92392250-1AA081D1-580C-49BC-BB8F-7A599F7BE5D8 @default.
- Q92392250 P17 Q92392250-29187426-595F-4DC9-9A52-C8D6DD8221A3 @default.
- Q92392250 P17 Q92392250-49C3382D-AB8F-46D5-B568-2B8791CA9388 @default.
- Q92392250 P17 Q92392250-A0028F4F-FEFB-4247-9C3B-6850C7747749 @default.
- Q92392250 P1813 Q92392250-6F369041-0EFF-4DAA-9131-985774C6465E @default.
- Q92392250 P2899 Q92392250-CD5F1B53-5E90-45D3-9804-7D426E8713B4 @default.
- Q92392250 P3098 Q92392250-3EF441E6-09A0-4D77-A6DD-08A47AABD2EC @default.
- Q92392250 P31 Q92392250-82D73499-7929-4194-B440-C99C285DA24E @default.
- Q92392250 P580 Q92392250-D55ACB38-A703-471E-B6DB-66B039C72EB2 @default.
- Q92392250 P582 Q92392250-BA5EA131-3BB5-454E-A9A2-4359FA4DCA6F @default.
- Q92392250 P6099 Q92392250-13A475DE-956A-4D5C-B979-28F2444D2618 @default.
- Q92392250 P8005 Q92392250-A3E05775-DE73-4885-AF97-8BA2AA472635 @default.
- Q92392250 P8363 Q92392250-2F96A1A7-CF34-4063-B55A-25B83B23E916 @default.
- Q92392250 P1050 Q103177 @default.
- Q92392250 P1132 "+230" @default.
- Q92392250 P1476 "A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection" @default.
- Q92392250 P17 Q29 @default.
- Q92392250 P17 Q30 @default.
- Q92392250 P17 Q40 @default.
- Q92392250 P17 Q801 @default.
- Q92392250 P1813 "Coronavirus" @default.
- Q92392250 P2899 "+18" @default.
- Q92392250 P3098 "NCT04349098" @default.
- Q92392250 P31 Q30612 @default.
- Q92392250 P580 "2020-04-17T00:00:00Z" @default.
- Q92392250 P582 "2020-08-31T00:00:00Z" @default.
- Q92392250 P6099 Q42824440 @default.
- Q92392250 P8005 Q76649708 @default.
- Q92392250 P8363 Q78089383 @default.